Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel U Dignass

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Zeitschrift Fur Gastroenterologie|February 19, 2020
[August 2019 - AWMF-Registriernummer: 021-009]Torsten Kucharzik, Axel U Dignass, Raja Atreya, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 21, 2009
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitisAxel U Dignass, Bernd Bokemeyer, Henning Adamek, et al.
Zeitschrift Fur Gastroenterologie|November 19, 2019
[August 2019 - AWMF-Registriernummer: 021-009]Torsten Kucharzik, Axel U Dignass, Raja Atreya, et al.
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Journal of Crohn'S & Colitis|March 2, 2016
European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's DiseaseFlorian Rieder, Giovanni Latella, Fernando Magro, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Zeitschrift Fur Gastroenterologie|February 19, 2020
[August 2019 - AWMF-Registriernummer: 021-009]Torsten Kucharzik, Axel U Dignass, Raja Atreya, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 21, 2009
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitisAxel U Dignass, Bernd Bokemeyer, Henning Adamek, et al.
Zeitschrift Fur Gastroenterologie|November 19, 2019
[August 2019 - AWMF-Registriernummer: 021-009]Torsten Kucharzik, Axel U Dignass, Raja Atreya, et al.
BMJ Open Gastroenterology|February 15, 2022
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitisEdouard Louis, Kristine Paridaens, Sameer Al Awadhi, et al.
Intestinal Research|April 15, 2022
The impact of clinical experience on decision-making regarding the treatment and management of mild-to-moderate ulcerative colitisJae Hee Cheon, Kristine Paridaens, Sameer Al Awadhi, et al.
Scandinavian Journal of Gastroenterology|December 21, 2021
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitisAxel U Dignass, Kristine Paridaens, Sameer Al Awadhi, et al.
Journal of Crohn'S & Colitis|March 2, 2016
European Crohn's and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn's DiseaseFlorian Rieder, Giovanni Latella, Fernando Magro, et al.
Inflammatory Bowel Diseases|August 29, 2009
Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitisDaniel C Baumgart, Stephan R Targan, Axel U Dignass, et al.
Pageof 4